Genomics startup ecosystem
We track 4 organisations in this sector across 3+ countries.
Showing 4 of 4 Genomics
Countries in this sector
Sectors alongside this one
Genomics results
-
GenePlanet
GenePlanet was founded in 2008 by Marko Bitenc and Nina Šterk and is the leading European provider of preventive genetic tests, including non-invasive prenatal testing (NIPT), cancer screening, and lifestyle DNA tests. The company cooperates with more than 500 clinics, hospitals, and insurance firms worldwide and markets its products under brands including NutriFit. In July 2023 GenePlanet closed a €20 million Series B round led by BlackPeak Capital, bringing total funding to approximately $34 million. It was ranked among the 1,000 fastest-growing companies in Europe by the Financial Times.
-
Jurgi Camblong
Co-founder and CEO of SOPHiA GENETICS, the Lausanne-based clinical AI company he co-founded in 2011 as an EPFL spin-out. Camblong led SOPHiA GENETICS for over a decade from a university genomics project to a Nasdaq IPO in July 2021, raising $228M and building a federated clinical AI network used by over 780 healthcare institutions in 70 countries for genomic analysis in oncology and rare disease diagnostics.
-
MSInsight
Develops MSIcare, bioinformatics software that analyses microsatellite instability biomarkers from next-generation sequencing data to guide oncologists in selecting targeted immunotherapy across cancer types. Winner of France's i-Lab 2023.
-
Sophia Genetics
SOPHiA GENETICS is a Lausanne-based health-tech company founded in 2011 by Jurgi Camblong and Pierre Hutter as an EPFL spin-out. The company built a clinical AI platform — SOPHiA DDM — that enables hospital and laboratory networks to decode genomic data for oncology, rare disease, and pharmacogenomics applications. Its platform standardises and accelerates genomic analysis across a federated network of more than 780 healthcare institutions in 70 countries, turning each new clinical dataset into a contribution to a collectively smarter system. SOPHiA GENETICS listed on Nasdaq in July 2021, raising $228M, and is backed by Salesforce Ventures and Generation Investment Management. The company represents the EPFL ecosystem's capacity to produce globally significant clinical technology at scale.
